Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection

Overview of attention for article published in International Journal of Bipolar Disorders, July 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

blogs: 1 blog
policy: 1 policy source

twitter: 1 X user
facebook: 1 Facebook page

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 47 Mendeley

Summary Blogs Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

An Overview of Pharmacogenomic Testing for Psychiatric Disorders

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.